MediciNova's Ibudilast And The Phase IIb Trial Offer Steady Outlook


I/we have no positions in any stocks mentioned, but may initiate a long position in MNOV over the next 72 hours. I wrote this article myself, and it expresses my own opinions.



from Biotech News